# Phase 3 and Extensional Study of Besifovir

> **NCT01937806** · PHASE3 · UNKNOWN · sponsor: **IlDong Pharmaceutical Co Ltd** · enrollment: 197 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** besifovir 150mg
- **DRUG:** tenofovir 300mg

## Key facts

- **NCT ID:** NCT01937806
- **Lead sponsor:** IlDong Pharmaceutical Co Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-10
- **Primary completion:** 2016-02
- **Final completion:** 2023-01
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01937806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01937806, "Phase 3 and Extensional Study of Besifovir". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01937806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*